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Introduction
Leukocyte trans-endothelial migration (TEM) is a key event in 
host defense. The passage of leukocytes across the vascular wall 
into the underlying tissues can be divided into distinct phases, 
including fi  rm adhesion of leukocytes to the endothelium and 
subsequent diapedesis (Vestweber, 2002; Johnson-Leger and 
Imhof, 2003; van Buul and Hordijk, 2004; for review see Muller, 
2003). Leukocyte adhesion to the endothelium initiates the for-
mation of dynamic dorsal membrane protrusions, assembling 
a cuplike structure, which surrounds adherent leukocytes and con-
tains the cell adhesion molecules intercellular adhesion molecule-1 
(ICAM1) and VCAM1 (Barreiro et al., 2002; Carman et al., 
2003; Carman and Springer, 2004). They have been referred to 
as docking structures (Barreiro et al., 2002) or trans-migratory 
cups (Carman and Springer, 2004). Little is known about the 
mechanisms that regulate their assembly, and their role in TEM 
remains uncertain.
During TEM, leukocytes adhere to ICAM1 on the endo-
thelial cell surface, and this triggers diverse intracellular signals 
(Vestweber, 2002; Kluger, 2004). Engagement of ICAM1 can 
be mimicked by cross-linking ICAM1 with ICAM1-specifi  c 
  antibodies (Wojciak-Stothard et al., 1999; Etienne-Manneville 
et al., 2000; Thompson et al., 2002) or by beads coated with anti-
bodies against ICAM1 (Tilghman and Hoover, 2002). Actin 
  dynamics in endothelial cells are important for leukocyte TEM, 
which is prevented by inhibiting endothelial actin polymeriza-
tion by cytochalasin D (Adamson et al. 1999; Carman and 
Springer, 2004). Cross-linking of ICAM1 stimulates the assem-
bly of actin stress fi  bers (Wojciak-Stothard et al., 1999; Van 
Buul et al., 2002). In addition, actin polymerization is involved 
in assembly of the cups (Carman and Springer, 2004).
Actin membrane dynamics are controlled by small Rho-
like GTPases. These proteins function as molecular switches 
and cycle between an inactive GDP-bound state and an active 
GTP-bound state. Blocking RhoA activity using Clostridium 
botulinum C3 transferase prevents the adhesion or migration 
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uring trans-endothelial migration (TEM), leukocytes 
use adhesion receptors such as intercellular adhe-
sion molecule-1 (ICAM1) to adhere to the endo-
thelium. In response to this interaction, the endothelium 
throws up dynamic membrane protrusions, forming a cup 
that partially surrounds the adherent leukocyte. Little is 
known about the signaling pathways that regulate cup 
formation. In this study, we show that RhoG is activated 
downstream from ICAM1 engagement. This activation re-
quires the intracellular domain of ICAM1. ICAM1 colocalizes 
with RhoG and binds to the RhoG-speciﬁ  c SH3-containing 
guanine-nucleotide exchange factor (SGEF). The SH3 
  domain of SGEF mediates this interaction. Depletion of 
endothelial RhoG by small interfering RNA does not affect 
leukocyte adhesion but decreases cup formation and in-
hibits leukocyte TEM. Silencing SGEF also results in a sub-
stantial reduction in RhoG activity, cup formation, and TEM. 
Together, these results identify a new signaling pathway 
involving RhoG and its exchange factor SGEF downstream 
from ICAM1 that is critical for leukocyte TEM.
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of leukocytes across endothelial cell monolayers (Adamson 
et al., 1999; Wojciak-Stothard et al., 1999). However, the role 
of RhoA in the assembly of the cups is unclear. Barreiro et al. 
(2002) reported that assembly of these structures induced by 
VCAM1 is inhibited by Y27632, an inhibitor of Rho-  associated 
coil-containing protein kinase (ROCK)/Rho kinase, which 
is a downstream effector of RhoA. In contrast, Carman and 
Springer (2004) found that treatment with Y27632 or C3 was 
Figure 1.  Endothelial cells protrude ICAM1-expressing 
membrane rufﬂ   es around an adhered HL60 cell. 
(A) TNF-α–treated endothelial cells were incubated with 
HL60 cells for 30 min, processed, and stained for ICAM1 
in green and for VE-cadherin in red. Confocal imaging 
shows that ICAM1 is recruited to sites of leukocyte 
  adhesion at the baso-lateral focal plane (a) and as a 
ring structure surrounding the leukocyte at the apical 
  focal plane (b). (B) Z-stack imaging shows ICAM1 staining 
in green (a) surrounding a leukocyte, which is stained for 
F-actin in red (asterisks; b). Image c shows the merge. 
Reconstruction of the Z-stack imaging shows ICAM1 
surrounding a leukocyte in a cup-like structure (green, d). 
Vertical bar at the right shows the height of the pro-
trusions (6 μm). (C) TNF-α–treated endothelial cells 
transiently transfected with GFP-actin were incubated 
with HL60 cells for 30 min, processed, and imaged for 
GFP-actin in green (a and e), ICAM1 in red (b and f), 
merge of GFP-actin and ICAM1 in yellow (c and g), 
and F-actin using phalloidin in white to visualize the 
  adhered leukocyte (d and h). Confocal imaging re-
vealed that actin and ICAM1 are recruited to sites of 
leukocyte adhesion, surrounding the leukocyte at the 
apical plane (e–h). (D) Scanning EM images show pro-
truding endothelial membrane sheets (arrowheads) around 
adhered HL60 cells (asterisks). Bars (A), 10 μm; (B and C) 
5 μm; (D) 1 μm.ICAM1-INDUCED RHOG ACTIVATION • VAN BUUL ET AL. 1281
unable to prevent cup formation downstream from ICAM1 
  engagement. The similarity of these apical cups to phago-
cytic cups (Barreiro et al., 2002; Carman et al., 2003) together 
with the role of RhoG in the phagocytosis of apoptotic cells 
(deBakker et al., 2004) has led us to examine whether RhoG 
may contribute to the formation of endothelial cups and par-
ticipate in TEM.
In this study, we demonstrate that RhoG is a critical medi-
ator of leukocyte TEM. RhoG and a guanine-nucleotide ex-
change factor (GEF) for RhoG, SH3-containing GEF (SGEF), 
are recruited to sites of ICAM1 engagement, where RhoG be-
comes activated. We fi  nd that ICAM1 interacts with SGEF 
through its SH3 domain. Finally, reduction of RhoG or SGEF 
expression in endothelial cells using siRNA decreases the as-
sembly of the cups as well as the migration of leukocytes across 
endothelial cell monolayers.
Results
Endothelial cells form apical cups 
around leukocytes
Adhesion of myeloid leukemia HL60 cells to TNF-α–activated 
endothelial cells induced not only the recruitment of ICAM1 to 
sites of adhesion (Fig. 1 A) but also ICAM1-positive membrane 
protrusions that surrounded the adhered leukocyte (Fig. 1 B), 
which is consistent with previously reported fi  ndings (Barreiro 
et al., 2002; Carman et al., 2003). Also, GFP-actin, which is 
transiently expressed in endothelial cells, distributed to sites 
of leukocyte binding and colocalized with ICAM1 (Fig. 1 C). 
Of note, the endothelial cell–cell junctional marker vascular 
endothelial (VE) cadherin did not localize to these membrane 
protrusions (Fig. 1 A). Three-dimensional projections showed 
that ICAM1-positive protrusions arose from the apical plane of 
the endothelial cells but did not fully cover the leukocyte (Fig. 
1 B). These protrusions resembled cuplike structures that extended 
 6–7 μm above the baso-lateral membrane (Fig. 1 B, d). To 
determine whether these ICAM1-rich cups formed around cells 
that were transmigrating, HL60 cells were plated on endothelial 
monolayers growing on transwell fi  lters. Confocal analysis of 
fi  xed and stained preparations revealed rings of ICAM1 stain-
ing at the apical surface (i.e., cups) surrounding cells that were 
traversing the monolayer (Fig. S1, available at http://www.jcb
.org/cgi/content/full/jcb.200612053/DC1). Scanning EM con-
fi  rmed the presence of endothelial cuplike protrusions surroun-
ding but not fully covering leukocytes 30 min after leukocyte 
adhesion (Fig. 1 D).
RhoG and SGEF are enriched in dorsal 
membrane rufﬂ  es
The small GTPase RhoG and its specifi  c GEF, SGEF, are 
known to induce dorsal ruffl   es (Ellerbroek et al., 2004). 
RhoG and SGEF are endogenously expressed in endothelial 
cells as well as in COS7 and HeLa cells (Fig. 2 A). Over-
expression of the constitutively active mutant RhoG-Q61L or 
Figure 2.  RhoG and SGEF are expressed endogenously in 
endothelial cells and are localized to dorsal endothelial mem-
brane protrusions. (A) Western blot analysis of tissue lysates 
of mouse brain (a positive control for SGEF), HUVECs, HeLa, 
and COS7 cells show the endogenous expression of SGEF 
(100 kD; top blot) and RhoG (18 kD; bottom blot). (B) Endo-
thelial cells were transiently transfected with GFP–RhoG-Q61L (a) 
or GFP-SGEF (b) and stained for F-actin in red. Images re  present 
the merge. Arrowheads show membrane rufﬂ  es. JCB • VOLUME 178 • NUMBER 7 • 2007  1282
SGEF in endothelial cells induced ruffl  es on the apical sur-
face (Fig. 2 B).
To study the involvement of ICAM1 in the regulation of dor-
sal ruffl  es, COS7 cells that lack endogenous ICAM1 were used. 
The expression of ICAM1 tagged with GFP or the V5   epitope in 
COS7 cells showed distributions similar to ICAM1 in endothe-
lial cells (Fig. 3 A). Interestingly, cotransfection of RhoG-Q61L 
or SGEF not only induced dorsal ruffl  es but also induced a 
redistribu  tion of ICAM1 to these ruffl  es (Fig. 3, A and B; and 
Videos 1 and 2, available at http://www.jcb.org/cgi/content/full/
jcb.200612053/DC1). ICAM1 colocalized with RhoG-Q61L or 
SGEF (Fig. 3, A and B). The localization of ICAM1 to ruffl  es re-
quired active RhoG because neither wild-type (wt) RhoG nor a 
dominant-negative mutant, T17N, colocalized with ICAM1 (un-
published data). As a control, transmembrane protein PECAM-1 
was expressed together with RhoG-Q61L or SGEF and showed 
no colocalization (unpublished data). These data suggested a role 
for RhoG and SGEF in the formation of endothelial apical cup 
structures; therefore, we next tested the involvement of RhoG 
and SGEF in ICAM1 signaling and cup formation.
Figure 3.  SGEF and RhoG-Q61L colocalized 
with ICAM1. (A) COS7 cells were transiently 
  cotransfected with ICAM1-GFP (a and g) or 
ICAM1-V5 (d) and with GFP–RhoG-Q61L (e) or 
myc-SGEF (h). Image b shows F-actin. Images c, 
f, and i represent the merge. ICAM1 colocalizes 
with RhoG-Q61L and SGEF. Moreover, RhoG-
Q61L and SGEF induce a change in ICAM1 
distribution from spikes (a) to rufﬂ  es (arrowheads; 
d and g). (B) COS7 cells were transiently co-
transfected with ICAM1-GFP (a and d), myc-
SGEF (b), or myc-RhoG-Q61L (e). Panels c and 
f show merged images. Confocal x-z section 
  images show colocalization between ICAM1 
and SGEF (a–c) and ICAM1 and RhoG-Q61L 
(d–f) in dorsal membrane rufﬂ  es (arrowheads). 
Bars (A), 20 μm; (B) 10 μm.ICAM1-INDUCED RHOG ACTIVATION • VAN BUUL ET AL. 1283
Recruitment of ICAM1-GFP to sites 
of adhesion
COS7 cells lacking endogenous ICAM1 were used to express 
ICAM1-GFP. Incubation of these COS7 cells with HL60 cells 
resulted in the majority of HL60 cells adhering to the ICAM1-
GFP–transfected cells (Fig. 4 A). Three-dimensional  projections 
showed that ICAM1-positive protrusions surrounded the ad-
hered HL60 cells (Fig. 4 A, d), similar to those observed with 
endothelial cells (Fig. 1 B). To specifi  cally study ICAM1 en-
gagement and downstream signaling that would mimic leuko-
cyte binding to ICAM1, beads coated with antibodies against 
ICAM1 were used as described in Materials and methods 
Figure 4.  HL60 cells and beads coated with 
ICAM1 antibodies recruited ICAM1-GFP. (A) 
COS7 cells were transiently transfected with 
ICAM1-GFP (a). HL60 cells were allowed to 
adhere for 30 min. Samples were ﬁ  xed, per-
meabilized, and stained for F-actin (b). Image c 
shows the merge of images a and b. Note that 
the majority of the HL60 cells adhere to the 
ICAM1-GFP–expressing cells. Image d shows an 
x-z projection of ICAM1-GFP in green (arrow-
heads) that surrounds adhered HL60 cells 
(asterisks) stained with F-actin in red. (B) αICAM1 
beads added for 30 min to ICAM1-GFP–
expressing COS7 cells. Beads were stained with 
secondary AlexaFluor594 anti–mouse anti-
bodies in red (b). Image c shows merge of 
images a and b, with additional F-actin distri-
bution in white. Note that the majority of the 
αICAM1 beads adhere to the ICAM1-GFP–
  expressing cells. Image d shows x-z projection of 
ICAM1-GFP in green (arrowheads) that surrounds 
adhered αICAM1 beads (asterisks). (C) Scan-
ning EM image shows endothelial membrane 
sheets (arrowheads) that surround an αICAM1 
bead (asterisk). Bars, (A and B, panel c), 20 μm; 
(A and B, panel d) 5 μm; (C) 1 μm.JCB • VOLUME 178 • NUMBER 7 • 2007  1284
(see Bead adhesion assay section; Tilghman and Hoover, 2002). 
These beads, which are hereafter referred to as αICAM1 beads, 
specifi  cally adhered to ICAM1 and recruited ICAM1-GFP within 
30 min (Fig. 4 B and Video 3, available at http://www.jcb.org/
cgi/content/full/jcb.200612053/DC1). X-Z projections showed 
that ICAM1-GFP protruded around adhered αICAM1 beads 
(Fig. 4 B, d). Additionally, scanning EM images revealed that 
adhe sion  of  αICAM1 beads induced dorsal ruffl  es comparable 
with those induced by leukocytes (Fig. 4 C). The αICAM1 beads 
did not bind to VCAM1-GFP–transfected cells or to nontransfected 
Figure 5.  Beads coated with ICAM1 antibodies recruited SGEF and active RhoG to sites of adhesion. (A) As a control, cells expressing GFP alone and 
ICAM1-V5 were incubated with αICAM1 beads. ICAM1 mAbs are used to visualize ICAM1-V5. αICAM1 beads are stained with secondary AlexaFluor anti-
bodies that also stained ICAM1 in red (a). Images show that GFP alone (green; b) is not recruited around αICAM1 beads that adhered to ICAM1-V5 (arrow-
heads; a–c). Image c shows the merge. Image d shows a magniﬁ  cation of image c. GFP-SGEF (f) and GFP–RhoG-Q61L (j) are recruited (arrowheads) to 
αICAM1 bead adhesion sites on ICAM1-V5–expressing COS7 cells (e and i). Merged images are shown in g and k. Images h and l show magniﬁ  cations 
of g and k, respectively. (B) Quantiﬁ  cation of GFP-expressing proteins that are recruited to adhesion sites induced by αICAM1 beads. All cells were trans-
fected with ICAM1-V5 and subsequently cotransfected with GFP-tagged proteins except for single-transfected ICAM1-GFP. αICAM1 beads recruit ICAM1-
GFP, GFP-SGEF, and GFP–RhoG-Q61L in 55–80% of the cases to sites of adhesion. In contrast, GFP, β-catenin–GFP, and VE-cadherin–GFP are not recruited. 
Data are means ± SEM (error bars) of at least four independent experiments. Bars (A, panel c), 10 μm; (A, panels d, h, and l) 5 μm; (A, g and k) 20 μm.ICAM1-INDUCED RHOG ACTIVATION • VAN BUUL ET AL. 1285
cells (unpublished data). In addition, blocking antibodies to 
ICAM1 completely inhibited binding of the αICAM1 beads to 
ICAM1 (unpublished data).
RhoG and SGEF are recruited to sites 
of ICAM1 engagement
To show that ICAM1-GFP was recruited specifi  cally to the 
beads, cotransfections with ICAM1-V5 and GFP as a control 
were performed and revealed that GFP alone was not recruited 
to sites of adhesion (Fig. 5 A). Also, neither β-catenin–GFP nor 
VE-cadherin–GFP was recruited to sites of adhesion (Fig. 5 B). 
In contrast, GFP-SGEF and GFP–RhoG-Q61L were recruited 
to sites of ICAM1 engagement (Fig. 5, A and B). Additionally, 
as a control, beads coated with major histocompatibility complex 
(MHC) antibodies were incubated on human umbilical vein endo-
thelial cells (HUVECs), and z-stack analysis was performed to 
measure actin-rich protrusions around adhered beads. The re-
sults revealed that αICAM1 beads induced substantially more 
F-actin–rich protrusions than the αMHC class I beads, whereas 
the total number of beads that adhered to the endothelium was 
equivalent (Fig. S2 A, available at http://www.jcb.org/cgi/
content/full/jcb.200612053/DC1). Expression of GFP–RhoG-
Q61L in HUVECs showed that RhoG is recruited by αICAM1 
beads but not by αMHC class I beads (Fig. S2 B). Previous work 
has indicated that actin is a major component of the ICAM1-
positive cup structures (Barreiro et al., 2002; Carman et al., 2003; 
Carman and Springer, 2004). Using GFP-actin, which is tran-
siently expressed in endothelial cells, we confi  rmed that αICAM1 
beads effi  ciently recruited actin to sites of adhesion (Fig. S2 C). 
These data indicate that ICAM1 specifi  cally induces these pro-
trusions and recruits RhoG to sites of adhesion.
ICAM1 engagement activates RhoG
We next performed RhoG activation assays to determine RhoG 
activity downstream from ICAM1 engagement. We made use of 
the RhoG downstream effector ELMO (engulfment and cell 
motility), which specifi  cally binds GTP-bound RhoG (Katoh and 
Negishi, 2003; Ellerbroek et al., 2004). In our initial experiments, 
Figure 6. RhoG is activated downstream 
from ICAM1. (A) HUVECs were transiently 
transduced with myc-RhoG-wt using adenovirus. 
αICAM1 beads were added as described in 
Materials and methods. Using GST-ELMO, 
activated RhoG was pulled down from the lysate 
and detected by Western blot analysis using 
anti-myc antibodies. The middle blot shows 
protein expression levels of myc-RhoG-wt in 
endothelial cell lysates. The graph on the right 
shows quantiﬁ   cation of two independent ex-
periments. (B) αICAM1 beads were added to 
TNF-α–stimulated endothelial cells as described 
in Materials and methods. Using GST-ELMO, 
activated endogenous RhoG was isolated and 
detected by Western blot analysis using anti-
RhoG mAbs. (A and B) αICAM1 beads increased 
RhoG activity in endothelial cells within 30 min 
(top). The bottom panel shows endogenous 
ICAM1 expression in endothelial cell lysates. 
(B) The middle panel shows expression levels of 
endogenous RhoG in endothelial cell lysates. 
(C) COS7 cells were transiently transfected with 
myc-RhoG-wt and ICAM1-GFP. αICAM1 beads 
were added as described in Materials and 
methods. Using GST-ELMO, activated RhoG was 
isolated and detected by Western blot analysis 
using anti-myc antibodies. αICAM1 beads in-
creased RhoG activity up to 30 min (top). The 
middle panel shows expression levels of myc-
RhoG-wt in cell lysates. The bottom panel shows 
ICAM1-GFP expression detected by anti-GFP 
antibodies in cell lysates. (D) Experiments 
were performed as in B, but with HL60 cells 
(5 × 10
5 cells per six wells). Single-transfected 
myc-RhoG-Q61L-COS7 cells were used as a 
positive control. The top panel shows that HL60 
cell adhesion increased RhoG-GTP levels. The 
middle panel shows levels of transfected myc-
RhoG-wt, and the bottom panel shows levels 
of ICAM1-GFP. (B–D) The graph on the right 
shows quantiﬁ  cation of three independent exper-
iments. Data are means ± SEM (error bars). 
*, P < 0.05; **, P < 0.01.JCB • VOLUME 178 • NUMBER 7 • 2007  1286
we used an adenoviral vector to deliver myc-tagged RhoG to 
HUVECs and found that engagement of ICAM1 with αICAM1 
beads induced RhoG activation (Fig. 6 A). Examining the acti-
vation of endogenous RhoG using a monoclonal antibody re-
vealed that ICAM1 engagement showed a similar response (Fig. 
6 B). It should be noted that TNF-α pretreatment did not change 
the activity of RhoG in endothelial cells, although overnight 
treatment slightly diminished RhoG expression (unpublished data). 
To delineate the pathway downstream from ICAM1, myc-tagged 
RhoG-wt together with ICAM1-GFP were expressed in COS7 
cells as described in Materials and methods (see RhoG, RhoA, 
and Rac1 activation assay section). Treatment with αICAM1 
beads induced RhoG activation after 10 and 30 min (Fig. 6 C). 
This activation was transient because the induced activity of 
RhoG declined after 60 min (Fig. 6 B and Fig. S3 A, available 
at http://www.jcb.org/cgi/content/full/jcb.200612053/DC1). 
Beads coated with MHC class I antibodies did not induce any 
RhoG activation (Fig. S3 B). To examine whether leukocytes 
could activate RhoG through ICAM1, we added HL60 cells 
to myc–RhoG-wt and ICAM1-GFP–expressing COS7 cells. 
RhoG activation was stimulated by the adhesion of HL60 cells 
(Fig. 6 D). To study whether closely related GTPases Rac1 and 
Cdc42 are activated downstream from ICAM1 engagement, pull-
down assays using the p21-activated kinase–binding domain (PBD) 
as bait were performed. Interestingly, Rac1 and Cdc42 were tran-
siently activated downstream from ICAM1 engagement as well, 
although Rac1 activation peaked at 10 min (Fig. S3 C). RhoA 
activity measurements confi  rmed that RhoA became activated 
after ICAM1 engagement (Adamson et al. 1999; Wojciak-Stothard 
et al., 1999), and this was maximal after 10 min (Fig. S3 E).
ICAM1–intracellular domain is required 
for RhoG activation
Previously, it has been shown that the intracellular domain of 
ICAM1 is required for leukocyte passage across the endothe-
lium but is dispensable for the initial adhesion (Lyck et al., 2003; 
Sans et al., 2001). To investigate whether the intracellular domain 
of ICAM1 is required to transmit the signal that triggers RhoG 
activation, a C-terminal deletion mutant of ICAM1 lacking the 
intracellular domain and tagged to a V5 epitope (ICAM1-∆C-V5) 
Figure 7.  ICAM1 intracellular domain was 
required for RhoG localization and activation. 
(A) COS7 cells were transiently cotransfected 
with full-length ICAM1 tagged with V5 (b) or a 
C-terminal deletion mutant of ICAM1-V5 (ICAM1-
∆C-V5; e) and with GFP–RhoG-Q61L (a and d). 
Panels c and f show the corresponding merged 
images. ICAM1-∆C-V5 does not colocalize with 
RhoG-Q61L. (B) Experiments were performed 
as described in Fig. 6 C except ICAM1-GFP 
has been replaced with V5-tagged ICAM1-wt 
(ICAM1-wt) or the V5-tagged C-terminal trun-
cated ICAM1 mutant (ICAM1-∆C). The top panel 
shows that ICAM1 engagement increases 
RhoG-GTP levels in cells expressing ICAM1-wt 
but not in cells expressing ICAM1-∆C. The 
bottom panel shows levels of myc-RhoG-wt in 
total cell lysates. The graph on the right shows 
quantiﬁ  cation of three independent experiments. 
*, P < 0.05. (C) ICAM1 intracellular tail was 
required for efﬁ   cient recruitment around an 
adhered leukocyte. Confocal imaging was 
used to visualize the apical and the baso-
lateral plane of the COS7 cells that were 
expressing either ICAM1-wt or ICAM1-∆C. 
Quantiﬁ  cation of ICAM1-rich rings around HL60 
cells that were allowed to adhere for 30 min 
showed a requirement of the ICAM1 tail for 
proper cup formation. The experiment was re-
peated three times. *, P < 0.01. (B and C) Data 
are means ± SEM (error bars). Bars, 20 μm.ICAM1-INDUCED RHOG ACTIVATION • VAN BUUL ET AL. 1287
was generated and expressed in COS7 cells. The overexpression 
of ICAM1-∆C-V5 together with GFP–RhoG-Q61L showed 
that ICAM1 required its intracellular domain to localize to 
RhoG-induced dorsal ruffl  es (Fig. 7 A). No difference in the 
adhesion of αICAM1 beads to either full-length or ICAM1-∆C 
was observed (unpublished data). However, the αICAM1 beads 
were unable to activate RhoG in cells expressing ICAM1-∆C 
(Fig. 7 B). Additionally, cells that expressed ICAM1-∆C in-
duced substantially less ICAM1-positive protrusions around ad-
hered leukocytes than ICAM1-wt (Fig. 7 C). Together, these data 
show that ICAM1 engagement induces RhoG activation and 
subsequent membrane protrusions in a pathway that is depen-
dent on its intracellular domain.
ICAM1 associates with SGEF through 
its SH3 domain
The fi  nding that RhoG is activated downstream from ICAM1 
engagement coupled with the observation that SGEF and RhoG 
colocalized with ICAM1 led us to investigate whether ICAM1 
and SGEF physically interact. Immunoprecipitation experiments 
showed that endogenous ICAM1 was precipitated with endo-
genous SGEF from TNF-α–treated endothelial cells (Fig. 8 A). 
To study this interaction in more detail, pull-down experi-
ments were performed using biotinylated peptides. A peptide 
corresponding to the cytoplasmic domain of ICAM1 bound 
myc-tagged SGEF as well as endogenous SGEF (Fig. 8, B and C, 
respectively). Interestingly, the intracellular domain of ICAM1 
comprises only 28 amino acids, and its C terminus contains four 
prolines in close proximity. We examined whether the SH3 do-
main of SGEF could directly associate with the cytoplasmic 
  domain of ICAM1. Biotinylated ICAM1–intracellular domain 
peptide sedimented the SH3 domain of SGEF, which was fused 
to GST (GST-SH3
SGEF) in vitro (Fig. 8 D, a). To further explore 
the interaction of SGEF with ICAM1, we used a myc-tagged 
mutant of SGEF lacking the SH3 domain (SGEF-∆SH3). This 
mutant SGEF failed to coimmunoprecipitate with ICAM1-GFP 
(Fig. 8 D, b). Interestingly, the association between SGEF 
and ICAM1 did not depend on the GEF activity of SGEF; 
ICAM1 still associated with a catalytically dead mutant of 
SGEF (SGEF-∆DH) that contained the SH3 domain (Fig. 8 D, b). 
An inactivating point mutant in the SH3 domain of SGEF (myc–
SGEF-W826R) was previously generated in which the catalytic 
activity of SGEF remained intact (Ellerbroek et al., 2004). 
This construct and SGEF-wt were overexpressed in COS7 cells 
together with ICAM1-GFP. Immunoprecipitation assays con-
fi  rmed that SGEF-wt interacted with ICAM1, but SGEF-W826R 
revealed decreased binding (Fig. 8 E). These data indicated that 
the ICAM1–SGEF interaction requires an intact SGEF-SH3 
domain. To test whether ICAM1 associates through its proline-
rich sequence to SGEF, we deleted this proline-rich sequence 
from the cytoplasmic domain of ICAM1. Immunoprecipitation 
studies revealed that ICAM1 lacking the proline-rich sequence 
failed to bind to SGEF (Fig. 8 F).
RhoG is required for leukocyte TEM
To study RhoG involvement in TEM, siRNA was used to reduce 
RhoG expression in primary endothelial cells. Western blot 
analysis revealed that the relevant siRNA reduced RhoG protein 
expression in endothelial cells but did not affect other proteins 
known to be present in cup structures or involved in transmigra-
tion, such as moesin and ICAM1 (Barreiro et al., 2002; Carman 
et al., 2003; Millán et al., 2006). Also, the expression levels of 
other closely related small GTPases such as Rac1, Cdc42, and 
RhoA were unaffected (Fig. 9 A). Adhesion of leukocytes to endo-
thelial monolayers that showed reduced RhoG expression was 
not affected. Similarly, expression of dominant-negative RhoG 
did not affect leukocyte adhesion (unpublished data). However, 
the formation of cup structures, which was quantifi  ed as ICAM1-
positive ringlike structures that surrounded adhered leukocytes, 
was decreased compared with control cells (Fig. 9 B). Trans-
migration of HL60 cells across endothelial cell monolayers 
was also substantially attenuated by the knockdown of RhoG 
expression (Fig. 9 C).
Several previous studies have addressed the role of RhoA 
in endothelial cells during leukocyte TEM, demonstrating that 
it is required for TEM (Adamson et al., 1999; Wojciak-Stothard 
et al., 1999) and showing that it becomes activated downstream 
from ICAM1 cross-linking (Wojciak-Stothard et al., 1999;  Etienne-
Manneville et al., 2000; Thompson et al., 2002). We were in-
terested to relate our RhoG results to this previous body of 
work on RhoA. Reducing RhoG expression by siRNA did not 
affect RhoA activation downstream of ICAM1 engagement 
(Fig. S4 A, available at http://www.jcb.org/cgi/content/full/
jcb.200612053/DC1), which is consistent with the activation 
of RhoA occurring faster than the activation of RhoG (Fig. S4, 
A and E). Interestingly, reducing RhoA expression by siRNA 
depressed ICAM1-induced RhoG activation (Fig. S4 B). This 
suggested that RhoA acts upstream of RhoG activation in the 
pathway from ICAM1 engagement. Whether RhoA has a role 
in cup formation has been controversial. Barreiro et al. (2002) 
found that inhibiting the RhoA effector ROCK/Rho kinase 
with Y27632 diminished cup formation. However, this was not 
found by Carman and Springer (2004), who also were unable 
to block cup formation by treating endothelial cells with C3 
or Y27632 (Carman et al., 2003). Our fi  nding that RhoA is 
required upstream of RhoG activation suggested that RhoA may 
be necessary for cup formation. Consequently, we investigated 
this directly using micro-RNA (miRNA) of RhoA to depress its 
expression. We have found that the depletion of RhoA reduced 
the formation of cups induced by αICAM1 beads (Fig. S4 C).
SGEF and leukocyte TEM
We wished to explore whether SGEF has a role in leukocyte 
TEM and, thus, have used siRNA to knockdown SGEF expres-
sion in endothelial cells. We confi  rmed that the siRNA decreased 
SGEF expression and that it did not affect the expression of 
RhoG, Rac1, or other proteins involved in cups, such as ICAM1 
or moesin (Fig. 10 A). Importantly, SGEF knockdown did im-
pair the activation of RhoG downstream from ICAM1 engage-
ment (Fig. 10 B), and, consistent with this, it also resulted in 
decreased cup formation, as judged by the number of ICAM1-
positive rings surrounding adherent leukocytes (Fig. 10 C). 
Together, these data indicate a pathway from ICAM1 clustering 
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Figure 8.  SGEF interacts through its SH3 domain with the 
C-terminal domain of ICAM1. (A) ICAM1 was immunoprecipi-
tated (IP) using anti-ICAM1 antibodies, and IgG was used as 
control. Immunoblotting with anti-SGEF antibodies showed 
that endogenous ICAM1 and SGEF interacted in endothelial 
cells, whereas IgG did not show any interaction with SGEF 
(top). The second panel shows that ICAM1 was efﬁ  ciently 
immunoprecipitated by anti-ICAM1 antibodies (left lane) but not 
by IgG (right lane). The two bottom panels show levels 
of endogenous SGEF and ICAM1 in endothelial cell lysates. 
(B) COS7 cells were transfected with myc-SGEF-wt, lysed, and 
subsequently incubated with biotinylated peptides that corre-
spond to the intracellular domain of ICAM1 (ICAM1-C-term.) 
or to the intracellular domain of αv-integrin, which was used 
as control (αv-C-term). Streptavidin-based pull-downs show 
that the intracellular domain of ICAM1 binds myc-SGEF. The 
right lane shows myc-SGEF expression in one tenth of the total 
cell lysate using anti-myc antibodies. (C) Endothelial cells were 
lysed and subsequently incubated with biotinylated peptides as 
described in B. The top panel shows that ICAM1-peptide 
bound endogenous SGEF, whereas the αv-C-term-peptide 
did not. (D, a) GST-SH3
SGEF (amino acids 789–850) was puri-
ﬁ   ed and incubated with the peptides described in B. Pull-
down experiments using streptavidin-coated Sepharose beads 
were performed, and GST-SH3
SGEF was detected using anti-
GST antibodies. SH3
SGEF interacted with the ICAM1 tail but 
not with the tail of αv-integrin (αv-C-term). (D, b) COS7 cells 
were transfected with ICAM1-GFP and myc-SGEF-∆DH or 
myc-SGEF-∆SH3 and were processed for immunoprecipitation 
using anti-GFP antibodies. Western blot analysis revealed 
that ICAM1-GFP binds to myc-SGEF that contains the SH3 do-
main independent of the DH domain. (E) COS7 cells were 
transiently cotransfected with ICAM1-GFP and myc-SGEF-wt 
or myc-SGEF-W826R. ICAM1-GFP was immunoprecipitated 
using anti-GFP antibodies. Immunoblotting with anti-myc anti-
bodies showed the binding of SGEF-wt but reduced binding 
of SGEF-W826R to ICAM1-GFP (top). The bottom blots show 
levels of immunoprecipitated ICAM1-GFP and myc constructs 
in total cell lysates as indicated. (F) COS7 cells were tran-
siently cotransfected with myc-SGEF-wt and ICAM1-wt-GFP or 
ICAM1-∆Proline (Pro). GFP was immunoprecipitated using 
anti-GFP antibodies. Immunoblotting with anti-myc antibodies 
showed the binding of SGEF-wt but reduced binding of SGEF-wt 
to ICAM1-∆Pro-GFP (top). The bottom blots show levels of 
immunoprecipitated ICAM1-wt-GFP or ICAM1-∆Pro-GFP and 
GFP and myc constructs in total cell lysates as indicated. Note 
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Finally, we examined the effect of SGEF knockdown on TEM 
and found that it caused a decrease in the migration of HL60 
cells across endothelial monolayers by up to 50% (Fig. 10 D).
Discussion
During the last decade, it has become increasingly clear that 
  endothelial cells, rather than being a passive barrier, actively par-
ticipate in the process of leukocyte TEM. This study focuses on a 
recently discovered phenomenon that occurs during TEM in which 
the endothelial cell extends sheets of membrane to form a cuplike 
structure that surrounds adherent leukocytes (Barreiro et al., 
2002; Carman et al., 2003; Carman and Springer, 2004; Doulet 
et al., 2006). Although their precise function is unclear, evidence 
has been presented that these structures assist leukocytes on 
their way through the endothelium (Carman and Springer, 2004).
Our data reveal a new signaling pathway downstream from 
leukocyte adhesion that involves the small GTPase RhoG. We 
show here that RhoG activation is triggered through the engage-
ment of ICAM1 and is critical for formation of the apical cups. 
Additionally, RhoG expression is needed for optimal leukocyte 
passage across the endothelium. Our data show a strong correla-
tion between formation of the cups and TEM. The endothelial 
apical cups resemble phagocytic cups, and it is notable that RhoG 
has been implicated previously in the phagocytosis of apoptotic 
cells in Caenorhabditis elegans (deBakker et al., 2004). Recent 
work has also implicated RhoG as well as its exchange factor 
SGEF in the uptake of Salmonella by epithelial cells (Patel and 
Galan, 2006). Engulfment of Salmonella is promoted by several 
bacterial proteins that function to activate multiple Rho family 
GTPases. Interestingly, the Salmonella protein SopB was found 
to activate SGEF and RhoG, thereby stimulating the formation 
of phagocytic cups on the surfaces of epithelial cells (Patel and 
Galan, 2006). Together, these results suggest that SGEF and 
RhoG may function in a variety of physiological and pathological 
situations in which phagocytosis or the uptake of particulate 
material is involved.
The route by which leukocytes pass through the endo-
thelium, whether it is paracellular or transcellular, has generated 
considerable debate for many years. In tissue culture models, 
it has been estimated that only 10–25% of all leukocytes use the 
transcellular route, with the majority migrating through cell–
cell junctions (Carman and Springer, 2004). Millán et al. (2006) 
have shown that the redistribution of ICAM1 to caveolin-rich 
membrane domains in response to engagement is followed by 
transcytosis to the baso-lateral side of the endothelium. The in-
duction of apical cups by RhoG as well as the similarity of these 
structures to phagocytic cups might lead to the idea that RhoG 
would function primarily in transcellular rather than paracellular 
migration. However, our data show that silencing RhoG re-
sults in >70% inhibition of leukocyte TEM. Although our work 
does not discriminate between the para- and trans-cellular mi-
gration routes, this decrease in TEM cannot be explained by 
blocking the trans-cellular pathway only. Consistent with this, 
the work of Carman and Springer (2004) suggests that trans-
migratory cups are not restricted to the trans-cellular route but 
may function to facilitate and guide leukocyte TEM in general. 
Alternatively, RhoG may have additional functions in TEM 
besides mediating cup formation.
The role of Rho family GTPases in formation of the cup 
structures has begun to be investigated. Barreiro et al. (2002) 
found that Y27632, which inhibits ROCK/Rho kinase down-
stream of RhoA, decreased the assembly of these structures in-
duced by VCAM1 engagement. However, Carman and Springer 
reported that neither C3 nor Y27632 inhibited the assembly of 
the cups induced by ICAM1 cross-linking (Carman et al., 2003; 
Figure 9.  Transmigration of HL60 cells and formation of cups depended 
on RhoG expression levels. (A) siRNA against RhoG efﬁ  ciently reduced the 
expression of endogenous RhoG in endothelial cells. Longer exposure did 
show some expression of RhoG. The siRNA did not affect the expression 
levels of RhoA, Rac1, Cdc42, tubulin, ICAM1, or moesin. (B) Quantiﬁ  cation 
of ICAM1-positive rings around adhered HL60 cells, which was measured 
as described in Materials and methods, showed that cup formation was 
signiﬁ  cantly decreased when RhoG expression was reduced. *, P < 0.01. 
(C) Endothelial cells were cultured on transwell ﬁ  lters and transfected with 
RhoG siRNA as described in Materials and methods. 48 h later, differenti-
ated HL60 cells were allowed to transmigrate for 4 h under spontaneous 
conditions (black bars) or to 50 ng/ml SDF-1 (white bars). Reduced endo-
thelial RhoG expression resulted in decreased spontaneous and SDF-1–
induced transmigration. *, P < 0.001; **, P < 0.01. (B and C) The 
experiment was repeated four times. Data are means ± SEM (error bars).JCB • VOLUME 178 • NUMBER 7 • 2007  1290
Carman and Springer, 2004). In our hands, we have observed 
the partial inhibition of cup formation by Y27632 (our unpub-
lished data) and have found that knockdown of RhoA also in-
hibits cup formation (Fig. S4 C). The depression of cup formation 
may, in part, be caused by the inhibition of RhoG activation in 
cells in which RhoA has been knocked down (Fig. S4 B). How 
RhoA regulates RhoG activation remains to be determined. In 
addition, RhoA may play other roles in the assembly of endo-
thelial apical cups.
In this study, we have focused on RhoG, a close relative of 
Rac1 (Wennerberg et al., 2002), because it induces dorsal mem-
brane ruffl  es and has been implicated in phagocytosis (deBakker 
et al., 2004). However, we have observed that ICAM1 engage-
ment leads to the activation of not only RhoG and RhoA but also 
Rac1 and Cdc42 (Figs. 6 and S3). It is notable that RhoG can 
activate Rac1 through the DOCK180-binding protein ELMO 
(Katoh and Negishi, 2003), raising the possibility that the acti-
vation of RhoG we observe stimulates Rac1 activation. How-
ever, the time course of the activation of Rac1 and RhoG is not 
consistent with this idea. In future work, it will be interesting to 
identify the pathways leading to the activation of these other 
Rho family members.
The intracellular domain of ICAM1 is a prerequisite for 
optimal TEM of leukocytes (Sans et al., 2001; Lyck et al., 2003). 
ICAM1 lacking its intracellular domain (ICAM1-∆C) fails 
to promote leukocyte TEM, although leukocyte adhesion to 
ICAM1-∆C is unaffected. Engagement of ICAM1-∆C by 
αICAM1 beads also fails to activate RhoG. The fact that ICAM1-
∆C cannot activate RhoG is likely the result of its inability to 
bind SGEF. We found that the proline-rich region of the intracel-
lular domain of ICAM1 binds the SH3 domain of SGEF. This 
interaction is independent of SGEF activation because catalyti-
cally inactive mutants of SGEF that express the SH3 domain still 
bind ICAM1. Engagement of ICAM1 does not promote the as-
sociation between SGEF and ICAM1 but does increase the 
activation of SGEF, as judged by the increased binding of SGEF to 
nucleotide-free RhoG (unpublished data). Thus, SGEF and 
ICAM1 likely form a stable interacting pair.
Additional signals such as tyrosine phosphorylation may 
be necessary to trigger SGEF activation, as has been shown for 
other GEFs (Rossman et al., 2005). One such signal may de-
pend on Src-kinase activity. Src-kinase is rapidly activated after 
ICAM1 engagement and is required for optimal leukocyte TEM 
but also does not affect leukocyte adhesion (Etienne-Manneville 
et al., 2000; Tilghman and Hoover, 2002; Wang et al., 2003; 
Yang et al., 2006a). Our preliminary results show that inhibiting 
Src family kinases using PP2 prevented RhoG activation down-
stream from ICAM1 engagement (unpublished data). These 
data support the idea that additional signals such as tyrosine 
phosphorylation are needed to activate SGEF. It is likely that 
there are multiple targets for Src downstream from ICAM1. 
One Src substrate that has been implicated in TEM is cortactin 
Figure 10.  Reducing SGEF expression in 
HUVECs blocked RhoG activation and TEM. 
(A) siRNA against SGEF reduces the expression 
of endogenous SGEF in endothelial cells. The 
siRNA did not affect the expression levels of 
endogenous RhoG, Rac1, ICAM1, or moesin. 
(B) Knockdown of SGEF expression by siRNA 
inhibits the activation of RhoG downstream 
from ICAM1. HUVECs were transiently trans-
duced with myc-RhoG-wt and treated with TNF-α. 
SGEF expression was reduced by siRNA in 
HUVECs, and RhoG activity, which was induced 
by αICAM1 beads, was measured using GST-
ELMO. The top panel shows RhoG activity 
  after 30 min, which was depressed when SGEF 
expression was reduced (bottom panel). The 
second panel shows equal expression for myc-
RhoG-wt in HUVECs. The third panel shows 
equal levels of ICAM1 in cell lysates. The 
bottom panel shows reduced SGEF expression 
after siRNA treatment in HUVECs. The experi-
ment was performed two times. (C) Knock-
down of SGEF expression decreased ICAM1 
cup formation. Endothelial cells transfected 
with SGEF siRNA were incubated with HL60 
cells. Quantiﬁ  cation of ICAM1-positive rings 
around adhered leukocytes, which was mea-
sured as described in Materials and methods, 
shows that cup formation was signiﬁ   cantly 
  decreased when SGEF levels were reduced. 
*, P < 0.05. (D) Knockdown of SGEF expres-
sion inhibited transmigration. Endothelial cells 
were cultured on transwell ﬁ  lters and trans-
fected with the appropriate siRNA as de-
scribed in Materials and methods. 48 h later, 
differentiated HL60 cells were allowed to 
transmigrate for 4 h under spontaneous conditions (black bars) or toward 50 ng/ml SDF-1 in the lower chamber (white bars). Reduced SGEF levels 
diminish SDF-1–induced transmigration signiﬁ  cantly. *, P < 0.001; **, P < 0.05. (C and D) The experiment was repeated nine times. Data are means ± SEM 
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(Yang et al., 2006b). Cortactin is a regulator of the actin cyto-
skeleton that is notably prominent in structures like membrane 
ruffl  es and phagocytic cups (Weed and Parsons, 2001).
The passage of leukocytes across the endothelium is a 
critical event in immune surveillance and in infl  ammation. 
 Although  infl  ammation is physiologically important, it also 
 underlies many pathological conditions. Consequently, there is 
considerable interest in understanding the pathways by which 
leukocytes cross the endothelial barrier so that inappropriate in-
fl  ammation can be controlled. Much remains to be learned about 
TEM, including the role of the cups that are formed in response 
to ICAM1 engagement. Different leukocyte types may induce 
different effects on the kinetics of ICAM1 signaling and sub-
sequent apical cup formation. In this study, we have identifi  ed a 
pathway downstream from ICAM1 involving RhoG and its ex-
change factor SGEF that leads to endothelial apical cup forma-
tion. Inhibition of either RhoG or SGEF not only inhibits apical 
cup formation but also depresses TEM, which is consistent with, 
although does not prove, a role for the cups in TEM.
Materials and methods
Reagents and antibodies
pAbs against ICAM1 (for Western blotting) and mAb against RhoA were 
obtained from Santa Cruz Biotechnology, Inc. mAbs against Rac1, Cdc42, 
and MHC class I (MHC-A, -B, and -C) were purchased from BD Bio-
sciences. Recombinant TNF-α and a mAb against ICAM1 were purchased 
from R&D Systems. The GFP and myc (clone 9E10) mAbs were purchased 
from Invitrogen. Polyclonal rabbit antibody against VE-cadherin was pur-
chased from Cayman Chemical. The SGEF rabbit pAb was generated 
in our laboratory as described previously (Ellerbroek et al., 2004). The 
mAb against RhoG (clone IF-3-B3-E5) was raised in the laboratory of 
M.A. Schwartz (Robert M. Berne Cardiovascular Research Center, University 
of Virginia, Charlottesville, VA) against the C-terminal RhoG peptide (AA162-
180) of the sequence Q  Q  D  G  V  K  E  V  F  A  E  A  V  R  A  V  L  N  P  T  . Dot blots showed that 
the mAb did not cross react with bacterially expressed Rac1, Cdc42, and 
RhoA. Western blotting analysis showed that the RhoG antibody did recog-
nize GFP–RhoG-wt but not GFP–Rac1-wt expressed in COS7 cells.
Expression vectors
SGEF cDNA was subcloned using BamHI–EcoRI restriction sites into pCMV6M, 
an N-terminal myc epitope–tagged eukaryotic expression vector, as described 
previously (Ellerbroek et al., 2004). SGEF deletion mutants were gener-
ated using the QuikChange Site-Directed Mutagenesis kit (Stratagene) 
and were subcloned into pCMV6M. pGEX-4T2-ELMO was a gift from 
K. Ravichandran (University of Virginia, Charlottesville, VA). Generation 
of eukaryotic expression vectors pCMV-myc-Rac(Q61L), pCMV-myc–Rac-wt, 
pCMV-myc-Rac(T17N), pCMV-myc-RhoG(Q61L), pCMV-myc–RhoG-wt, and 
pCMV-myc-RhoG(T17N) was described previously by our laboratory 
(Wennerberg et al., 2002). wt and mutant Rac1 and RhoG constructs were 
subsequently subcloned into pEGFP-C3 (CLONTECH Laboratories, Inc.) as 
described previously (Wennerberg et al., 2002). SGEF was subcloned into 
pEGFP-C2. ICAM1-GFP was a gift from F. Sanchez-Madrid (Hospital de la 
Princesa, Universidad Autónoma de Madrid, Madrid, Spain). For ICAM1-
∆Pro-GFP, the last 11 amino acids of the intracellular tail of ICAM1 were 
deleted. ICAM1-wt and C-terminal deletion mutant (lacking the last 28 
amino acids) cDNA was subcloned into the pAdCMV-V5-DEST vector using 
the Gateway expression system (Invitrogen).
Cell cultures, treatments, and transfections
HUVECs were obtained from Cambrex and cultured as described previously 
(Worthylake et al., 2001). Endothelial cells were activated with 10 ng/ml 
TNF-α overnight as indicated to mimic inﬂ  ammation. All cell lines were cul-
tured or incubated at 37°C at 10% CO2. The HL60 promyelocytic cell line 
was obtained from the University of North Carolina’s Lineberger Compre-
hensive Cancer Center Tissue Culture Facility and grown in Optimem plus 
5% FBS. In all experiments described, differentiated HL60 cells were used. 
Differentiation to a neutrophil-like lineage was achieved by adding 1.3% 
DMSO for 3–5 d (Back et al., 1992). COS7 cells were maintained in growth 
medium (Iscove’s modiﬁ  ed Dulbecco’s medium with 10% FCS; Sigma-
Aldrich). Cells were transiently transfected with the expression vectors indi-
cated in each experiment according to the manufacturer’s protocol using 
LipofectAMINE PLUS (Invitrogen) or Fugene 6 (Roche). Myc–RhoG-wt cDNA 
was transferred to an AdV expression vector and transfected into 293 cells, 
and high titer virus stocks were produced. Subsequently, myc–RhoG-wt was 
transiently delivered into HUVECs by adenovirus transduction.
Immunoﬂ  uorescence
Cells were cultured on glass coverslips, ﬁ  xed, and immunostained with the 
indicated primary antibodies for 60 min at RT as described previously (van 
Buul et al., 2002). Subsequent visualization was performed with Alexa-
Fluor-conjugated secondary antibodies for 30 min (Invitrogen). F-actin was 
visualized with ﬂ  uorescently labeled phalloidin (Invitrogen). Glass cover-
slips were mounted in MOWIOL at RT. Images were collected with a confo-
cal microscope (LSM510; Carl Zeiss MicroImaging, Inc.) equipped with a 
microscope (Axiovert 100M; Carl Zeiss MicroImaging, Inc.) and an oil im-
mersion plan-Neoﬂ  uar 63× NA 1.3 oil lens (Carl Zeiss MicroImaging, Inc.). 
Cross talk between the different channels was avoided by the use of se-
quential scanning. Images were processed using imaging examiner soft-
ware (Carl Zeiss MicroImaging, Inc.) and Photoshop CS (Adobe).
Scanning EM
Transfected cells were grown on glass coverslips, ﬁ  xed in 2.5% glutaral-
dehyde/PBS for 30 min at room temperature, and processed for scanning 
EM as described previously (Ellerbroek et al., 2004). In brief, samples 
were incubated with 2% aqueous osmium tetroxide for 45 min, dehydrated 
in a graded ethanol series, and critical point dried in liquid CO2 using a 
drying apparatus (CPD 010; Balzers Instruments). Samples were mounted 
on aluminum stubs (Ted Pella, Inc.) and sputter coated with gold/palladium 
using Polaron scanning EM. Cells were examined on a scanning electron 
microscope (model 820; JEOL) at 15 kV.
TEM assay
Migration assays were performed in transwell plates (Corning) of 6.5-mm 
diameter with 8-μm pore ﬁ  lters. Approximately 20,000 endothelial cells 
were plated on matrigel-coated transwell ﬁ  lters, which were treated the 
next day with siRNA as indicated. The following day, endothelial cells 
were treated with siRNA again and with 10 ng/ml TNF-α overnight at 
37°C and 10% CO2. 100,000 differentiated HL60 cells were added to the 
upper compartment, and HL60 cells were allowed to migrate to 50 ng/ml 
stromal cell–derived factor-1 (SDF-1; placed in the lower chamber to gener-
ate a chemotactic gradient; R&D Systems) for 4 h at 37°C and 10% CO2. 
An input control (i.e., 100,000 HL60 cells) was set as 100%. After collect-
ing the migrated HL60 cells, ﬁ  lters were inspected by confocal laser-
  scanning microscopy using ﬂ  uorescently labeled phalloidin to stain F-actin; 
coating of matrigel on the transwell ﬁ  lter did not affect the formation of a 
conﬂ  uent endothelial monolayer. Migrated HL60 cells were counted and 
compared with 100% input, and the percent migration of HL60 cells was 
calculated. To conﬁ  rm efﬁ  cient knockdown of the protein by siRNA, cells 
were simultaneously grown in six-well plates and equally treated with 
siRNA constructs and were analyzed by Western blotting.
Immunoprecipitation and Western blotting
Cells were grown to conﬂ   uency, washed twice gently with ice-cold 
Ca
2+- and Mg
2+-containing PBS, and lysed in 300 μl lysis buffer (25 mM 
Tris, 150 mM NaCl, 10 mM MgCl2, and 1% Triton X-100 with the addi-
tion of fresh protease inhibitors, pH 7.4). Immunoprecipitation was per-
formed as previously described (Barreiro et al., 2002) and analyzed by 
Western blotting using an enhanced ECL detection system (GE Healthcare). 
The intensity of the bands was quantiﬁ  ed by using ImageJ version 1.36 
(National Institutes of Health, Bethesda, MD).
Apical cup quantiﬁ  cation
Using confocal laser-scanning microscopy, z-stacks were taken to conﬁ  rm the 
formation of a cup around an adhered leukocyte. The length of the protru-
sion was  6–7μm above the baso-lateral plane of the substrate (Fig. 1 B, d). 
The apical plane was set to 4 μm from the baso-lateral plane (Fig. 1 A). 
ICAM1-positive rings in the apical plane were counted as positive cups.
RhoG, RhoA, and Rac1 activation assay
For RhoG activation assays, a transient coexpression of myc-tagged RhoG 
was used because of the lack of a high afﬁ  nity antibody that is appropriate 
for these assays (according to Katoh and Negishi [2003]). Transfected cells 
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1% Triton X-100, 1 mM PMSF, and 10 μg/ml each of aprotinin and leupeptin. 
Lysates were cleared at 14,000 g for 10 min. Supernatants were rotated 
for 30 min with 60–90 μg GST-ELMO (GST fusion protein containing 
the full-length RhoG effector ELMO) conjugated to glutathione–Sepharose 
beads (GE Healthcare). Beads were washed in 50 mM Tris, pH 7.4, 10 mM 
MgCl2, 150 mM NaCl, 1% Triton X-100, and protease inhibitors. Pull-downs 
and lysates were then immunoblotted for the myc epitope tag. For RhoA and 
Rac1, GST-Rhotekin and GST-PBD were used as baits, respectively, and 
used as described for GST-ELMO.
Fusion proteins
GST-ELMO, GST-SH3
SGEF (SGEF
789–850), GST-Rhotekin, and GST-PBD fusion 
proteins were puriﬁ  ed from BL21 Escherichia coli cells (Stratagene) using 
glutathione–Sepharose 4B as previously described (Ellerbroek et al., 2004). 
GST fusion proteins were eluted with free, reduced glutathione in TBS medium 
(50 mM Tris, 150 mM NaCl, 5 mM MgCl2, pH 7.4, and 1 mM DTT) and 
stored in 30% glycerol at −80°C.
Antibody-coated beads
3 μm polystyrene beads (Polysciences, Inc.) were pretreated with 8% glutar-
aldehyde overnight, washed ﬁ  ve times with PBS, and were incubated with 
300 μg/ml ICAM1/MHC mAb according to the manufacturer’s protocol.
Bead adhesion assay
For immunoﬂ  uorescence or scanning EM, 1 μg/ml of antibody-containing 
beads was washed and resuspended in culture medium. 1 μg/ml of antibody-
coated beads was incubated in wells of 24-well dishes containing glass 
coverslips, on which TNF-α–pretreated HUVECs or COS7 cells were 
cultured. After the appropriate time, unbound beads were removed, and 
coverslips were put on ice, gently washed three times with ice-cold PBS 
containing 1 mM Ca
2+/Mg
2+, and subsequently processed for immuno-
ﬂ  uorescence. For biochemistry, 10 μg/ml of antibody-coated beads were 
  incubated on the cells, after which cells were washed as described above 
(see Bead adhesion assay section) and subsequently lysed and processed 
as described (see Immunoprecipitation and Western blotting and RhoG, 
RhoA, and Rac1 activation assay sections).
Knockdown using siRNA
siRNA duplexes against human RhoG (sense, G  C  A  A  C  A  G  G  A  U  G  G  U  G  U-
C  A  A  G  U  U  ; antisense, 5′-P-U  C  G  U  C  C  A  A  G  A  U  C  G  A  C  A  U  C  C   UU) and SGEF 
mRNA (sense, C  A  A  A  U  G  G  C  C  U  U  G  C  C  G  C  U  A  A  U  U  ; antisense, 5′-P-U  U  A  G-
C  G  G  C  A  A  G  G  C  C  A  U  U  U  G  U  U  ) and siControl nontargeting siRNA were ob-
tained from the Dharmacon siRNA collection. HUVECs were transfected 
twice with 50 nmol/l siRNA using RNAifect transfection reagent (QIAGEN). 
After 48 h, cells were processed as described in the previous paragraph.
Knockdown using miRNA adenovirus
miRNA adenoviral constructs were engineered according to the manufac-
turer’s protocol (Invitrogen). In brief, two sets of DNA oligonucleotides were 
designed to target human RhoA mRNA and were named RhoA#1 and 
RhoA#2: T  G  C  T  G  A  A  G  A  C  T  A  T  G  A  G  C  A  A  G  C  A  T  G  T  C  G  T  T  T  T  G  G  C  C  A  C  T  G  A  C  T-
G  A  C  G  A  C  A  T  G  C  T  C  T  C  A  T  A  G  T  C  T  T   and C  C  T  G  A  A  G  A  C  T  A  T  G  A  G  A  G  C  A  T  G  T  C-
G  T  C  A  G  T  C  A  G  T  G  G  C  C  A  A  A  A  C  G  A  C  A  T  G  C  T  T  G  C  T  C  A  T  A  G  T  C  T  T  C   (RhoA#1) 
and G  C  T  G  T  T  T  C  C  A  T  C  C  A  C  C  T  C  G  A  T  A  T  C  T  G  T  T  T  T  G  G  C  C  A  C  T  G  A  C  T  G  A  C  A-
G  A  T  A  T  C  G  G  T  G  G  A  T  G  G  A  A  A   and C  C  T  G  T  T  T  C  C  A  T  C  C  A  C  C  G  A  T  A  T  C  T  G  T  C  A-
G  T  C  A  G  T  G  G  C  C  A  A  A  A  C  A  G  A  T  A  T  C  G  A  G  G  T  G  A  T  G  G  A  A  A  C   (RhoA#2). The 
oligonucleotides were annealed and ligated into pcDNA6 EmGFP. The 
EmGFP MiR RNA cassette was subsequently transferred to pDONR221 
and ﬁ  nally to pAd by two sequential Gateway BP and LR recombinations. 
Each construct was sequence veriﬁ  ed, and viral particles were produced 
by transfection in 293A cells.
Biotinylated peptides
Peptides were synthesized with the following sequence: ICAM1–intra-
cellular tail peptide; biotin-G  R  Q  R  K  I  K  K  Y  R  L  Q  Q  A  Q  K  G  T  P  M  K  P  N  T  Q  A  T  P  P  -OH; 
αv peptide; and biotin-G  H  E  N  G  E  G  N  S  E  T  -OH.
Live cell imaging
COS7 cells were cultured on glass coverslips and transfected with cDNA 
as indicated. After 24 h, cells were placed in a heating chamber at 37°C 
and recorded with a confocal microscope (LSM510; Carl Zeiss   MicroImaging, 
Inc.) equipped with a microscope (Axiovert 100M; Carl Zeiss MicroImaging, 
Inc.) and an oil immersion plan-Neoﬂ  uar 63× NA 1.3 oil lens (Carl Zeiss 
MicroImaging, Inc.).
Online supplemental material
Fig. S1 shows the recruitment of endogenous ICAM1 around a migrat-
ing HL60 cell. Fig. S2 shows the recruitment of GFP–RhoG-Q61L and 
F-actin to αICAM1 beads but not to αMHC class I beads. Fig. S3 shows 
activation of the small GTPases RhoG, Rac1, Cdc42, and RhoA down-
stream of ICAM1 engagement. Fig. S4 shows that reduced RhoG ex-
pression does not affect ICAM1-mediated RhoA activation but that the 
reduced expression of RhoA does inﬂ  uence RhoG activity downstream 
from ICAM1 engagement, which is induced by αICAM1 beads. Video 1 
shows a real-time recording of 10 min of GFP–RhoG-Q61L expression 
in COS7 cells. Video 2 shows a real-time recording of 10 min of GFP-
SGEF expression in COS7 cells. Video 3 shows a real-time recording of 
ICAM1-GFP expressed in COS7 cells and incubated with αICAM1 beads 
for 30 min. Online supplemental material is available at http://www.jcb
.org/cgi/content/full/jcb.200612053/DC1.
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